Pfizer, Valneva’s experimental Lyme disease vaccine shows 70% efficacy
HQ Team March 25, 2026: Pfizer Inc. and France-based Valneva SE‘s investigational vaccine has shown 70% efficacy in preventing Lyme disease in individuals.
Bharti Rana Jayshankar – Founder
She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.
Jay Shankar – Co-founder
He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.
HQ Team March 25, 2026: Pfizer Inc. and France-based Valneva SE‘s investigational vaccine has shown 70% efficacy in preventing Lyme disease in individuals.
Eight people have died in Rwanda due to Marburg virus disease and 26 others were confirmed to be infected by the illness —.
HQ Team March 7, 2024: The FDA has approved Pfizer’s Besponsa drug for pediatric patients aged one year and above to treat acute.
HQ Team December 9, 2023: The Centers for Disease Control and Prevention (CDC) has issued a health advisory after three people died following.
We use cookies to improve your experience on our site. By using our site, you consent to cookies.
Manage your cookie preferences below:
Essential cookies enable basic functions and are necessary for the proper function of the website.
Statistics cookies collect information anonymously. This information helps us understand how visitors use our website.
Google Analytics is a powerful tool that tracks and analyzes website traffic for informed marketing decisions.
Service URL: policies.google.com